Barclays upgrades Texas Instruments stock rating on industrial strength

Barclays upgraded Texas Instruments to Equalweight from Underweight and lifted its price target to $250 from $175, implying modest upside from the current $236.31 share price near its $238.80 52-week high. The firm cited stronger Industrial and Data Center trends, including March growth of more than 20% and more than 25% quarter-over-quarter, and expects Data Center to grow more than 90% in calendar 2026. Texas Instruments also reported Q1 2026 EPS of $1.68 versus $1.36 expected and revenue of $4.83B versus $4.52B expected, reinforcing the positive fundamental backdrop despite valuation concerns.

Analysis

TXN is a classic late-cycle re-rating setup where the market is starting to price an earnings inflection before the cycle is fully self-sustaining. The near-term upside is less about the absolute beat and more about the mix shift: Industrial and Data Center improvement reduces dependence on the weakest end markets, which typically matters more for multiple expansion than the headline EPS print. That said, the stock already discounts a lot of the good news, so the next leg likely depends on whether June/2H guidance can show sequential stability rather than just better-than-seasonal commentary.

The bigger second-order effect is competitive discipline. A stronger TXN signals that analog pricing has not fully rolled over, which is supportive for peers with similar product cycles and gross margin leverage, but it also means customers may accelerate qualification efforts to dual-source and reduce single-vendor exposure. If data center demand remains the main growth engine, watch for spillover into broader power management and connectivity suppliers; the market may rotate toward names with less valuation compression than TXN but similar cyclical exposure.

The contrarian concern is that this is becoming a quality-growth crowding trade disguised as cyclicality. At this valuation, the stock needs not just demand recovery but continued multiple support, and any hint that industrial growth normalizes back to seasonality could compress the multiple quickly. The setup is therefore asymmetric over weeks, not years: upside if management confirms sustained pricing and sequential orders, but downside if macro PMIs stall or end-market digestion shows up in the next two quarters.

For portfolio construction, the cleanest expression is relative, not outright. TXN is probably stronger than the average analog peer on fundamentals, but the risk/reward is no longer compelling enough to chase aggressively after a large rerating. The market may be underestimating how much of the move is already driven by multiple recovery rather than earnings power, which means the next catalyst has to be evidence of durability, not just recovery.

Key Decisions for Investors

• Hold TXN only as a relative-long vs weaker analog peers; pair long TXN / short a higher-leverage but slower-recovering semiconductor name over the next 1-3 months to capture continued quality rotation while limiting beta risk.
• Avoid initiating a fresh outright long in TXN at current levels unless June commentary confirms sequential upside; the risk/reward is poor after the rerating and any guidance disappointment could compress the multiple by 10-15%.
• If already long TXN, sell covered calls 1-2 quarters out against the position to monetize elevated implied expectations while retaining upside if the cycle inflects more strongly than the street expects.
• Watch for a breakdown in industrial PMIs over the next 4-8 weeks; if macro data softens, trim TXN on the first sign of order normalization because the stock’s valuation leaves little room for a false start.
• Use TXN as a hedge leg against higher-beta semiconductor longs: long TXN / short a more cyclical capex-dependent peer to express recovery without paying full multiple for the cycle.